Chugai Pharmaceutical (OTCMKTS:CHGCY) Shares Down 5.5% - Here's What Happened

Key Points

• Chugai Pharmaceutical's shares dropped 5.5% during mid-day trading, falling from a previous close of $23.56 to $22.27 with a significantly reduced trading volume of 17,418 shares.
• The company reported $0.23 earnings per share for the quarter, with a net margin of 33.08% and a return on equity of 20.80%, while analysts expect a total of 0.74 EPS for the fiscal year.
• Chugai Pharmaceutical has a market capitalization of $77.27 billion and its stock is trading below both its 50-day and 200-day simple moving averages, which stand at $22.76 and $24.46, respectively.

Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY - Get Free Report)'s share price traded down 5.5% during mid-day trading on Friday . The company traded as low as $21.78 and last traded at $22.27. 17,418 shares traded hands during trading, a decline of 91% from the average session volume of 201,498 shares. The stock had previously closed at $23.56.

Chugai Pharmaceutical Stock Performance

The firm has a market cap of $77.27 billion, a price-to-earnings ratio of 29.72 and a beta of 0.64. The stock's 50 day simple moving average is $22.76 and its 200-day simple moving average is $24.46.

Chugai Pharmaceutical (OTCMKTS:CHGCY - Get Free Report) last released its quarterly earnings data on Friday, October 24th. The company reported $0.23 earnings per share for the quarter. Chugai Pharmaceutical had a net margin of 33.08% and a return on equity of 20.80%. On average, analysts expect that Chugai Pharmaceutical Co., Ltd. Unsponsored ADR will post 0.74 EPS for the current fiscal year.

Chugai Pharmaceutical Company Profile

Chugai Pharmaceutical Co, Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.